A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|July 15, 2025
COBRRA Trial Results Raise Questions About VTE Management
The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
Related to this article
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Advertisement
Advertisement